|

Vyxeos Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: CPX-351, cytarabine and daunorubicin liposome, CPX-351, daunorubicin-cytarabine

Pipeline

Phase 1: 2

Top Sponsors

  • H. Lee Moffitt Cancer Center and Research Institute1
  • Children's Hospital Medical Center, Cincinnati1

Indications

  • Cancer2
  • Leukemia1
  • Acute Myeloid Leukemia1

Tampa, Florida1 trial

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Moffitt Cancer Center

Phase 1

Cincinnati, Ohio1 trial

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Cincinnati Children's Hospital Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.